ACTRN12619000714189已完成1 期
A single-dose, double-blind, placebo-controlled, randomised, crossover study of an oral cannabis-based medicine (ETC120) on sleep quality and quantity in adults with chronic insomnia disorder
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 25 Years 至 65 Years（—）
- 性别
- All
入选标准
- •1. Males and females aged 25 – 65 years old,
- •2. Chronic insomnia disorder diagnosed by a sleep physician or psychologist,
- •3. Insomnia Severity Index (ISI) score greater than or equal to 15,
- •4. Insomnia symptoms for more than 3 times per week and present for longer than 3 months,
- •5. Proficiency in English, and capable and willing to provide informed consent to the study procedures.
排除标准
- •1. Medical condition or medication that is the cause of the insomnia;
- •2. Known hypersensitivity to cannabinoids;
- •3. No reported use of cannabis within the past 3 months (or at the medical officer’s discretion) and confirmed by at least one negative urine drug screen (UDS);
- •4. Past or present history of cannabis dependence (ICD-10 criteria or at the medical officer’s discretion);
- •5. Sleep apnea (defined as Apnea Hypopnea Index [AHI] >15 and Oxygen Desaturation Index [ODI]>10) or sleep-related movement disorder based on in-laboratory polysomnography;
- •6. Delayed sleep phase syndrome (determined on clinical interview, actigraphy and sleep diary at screening);
- •7. Any medical condition related to an abnormal EEG (i.e. epilepsy, brain injury);
- •8. Shift-work, transmeridian travel (2 time zones) over the last one month;
- •9. History of major psychiatric disorder in the past 12 months except clinically-managed mild depression;
- •10. History of suicide attempt or current suicide ideation (score greater than 0 on Q9 to PHQ-9 at screening);
- •11. Current evidence of clinically significant disease [including participants who lack capacity and/or whose cognitive decline indicates disorientation to person/place/time and/or situation], or malignancy or chronic pain that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments;
- •12. Clinically relevant cardiovascular abnormalities as determined by 12-lead electrocardiogram (ECG) at screening;
- •13. Pregnancy or lactation - males and females shall be advised to use reliable contraception for the duration of drug therapy and a urine pregnancy test will be performed for female participants where necessary;
- •14. Use of any CNS-active drugs (including antidepressants, opioids, benzodiazepines) for the past 3 months or at the medical officer’s discretion;
- •15. Use of medications that may have a clinically significant impact upon the metabolism and excretion of cannabinoids at the medical officer’s discretion (e.g. CYP450 enzyme inducers/inhibitors);
- •16. History of drug or alcohol dependency or abuse within approximately the past 2 years;
- •17. Urinary drug test positive for drugs (cannabis, amphetamines, and cocaine) at screening visit;
- •18. Excessive caffeine use that in the opinion of the investigator contributes to the participant's insomnia, or if participant is unable to abstain from caffeine use 24 hours prior to and during each overnight sleep study;
- •19. Inability to refrain from alcohol consumption 24 hours prior to and during each overnight sleep study;
- •20. Individuals who regularly smoke or at the medical officer’s discretion;
- •21. Medical conditions that result in frequent need to get out of bed (e.g. nocturia);
- •22. Used any modality of treatment for insomnia, including CBT within 3 months before screening or at the medical doctor's discretion;
- •23. Unable to undergo MRI brain imaging due to implanted device (e.g. defibrillator, pacemaker) as identified via MRI screening questionnaire;
- •24. Required to complete mandatory drug testing (e.g. workplace testing, court order).
研究者
相似试验
进行中（未招募）
1 期
A single dose study to assess the effect of VAY736 in patients with primary Sjögren’s syndromeEUCTR2013-000250-22-DEovartis Pharma Services AG28
已完成
不适用
Phase 2a study for NASHKCT0008007J2H Biotech16
已完成
1 期
An assessment of the safety and pharmacokinetic of ascending doses of sanguinate (Trademark) in healthy volunteersACTRN12612001033831Prolong Pharmaceuticals24
已完成
1 期
Phase I study to assess the safety and tolerability of inhaled interferon-beta (IFN-beta1a) in controlled asthmatic male and female subjectsAsthmaISRCTN83107787Synairgen Research Limited (UK)40
已完成
不适用
Clinical trial to evaluate the safety and tolerability of CCX507-B in healthy subjectsISRCTN79241600ChemoCentryx, Inc. (USA)30